Zachary A Cooper

Zachary A Cooper

UNVERIFIED PROFILE

Are you Zachary A Cooper?   Register this Author

Register author
Zachary A Cooper

Zachary A Cooper

Publications by authors named "Zachary A Cooper"

Are you Zachary A Cooper?   Register this Author

64Publications

2755Reads

47Profile Views

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition.

J Exp Med 2017 06 27;214(6):1691-1710. Epub 2017 Apr 27.

Manchester Cancer Research Centre, Faculty of Biology, Medicine, and Health, School of Medical Sciences, Division of Molecular and Clinical Cancer Studies, The University of Manchester, Manchester M13 9PT, England, UK

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20160855DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460994PMC
June 2017

Targeted Therapies Combined With Immune Checkpoint Therapy.

Cancer J 2016 Mar-Apr;22(2):138-46

From the Departments of *Surgical Oncology and †Genomic Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000182DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478395PMC
January 2017

Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.

Mol Cancer Ther 2016 10 25;15(10):2442-2454. Epub 2016 Jul 25.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079683PMC
http://dx.doi.org/10.1158/1535-7163.MCT-15-0963DOI Listing
October 2016

Update on use of aldesleukin for treatment of high-risk metastatic melanoma.

Immunotargets Ther 2015 7;4:79-89. Epub 2015 Apr 7.

Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/ITT.S61590DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918260PMC
July 2016

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.

PLoS One 2015 13;10(10):e0140310. Epub 2015 Oct 13.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, United States of America; Dermatology and Cutaneous Biology Research Center, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0140310PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604168PMC
June 2016

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.

Cancer Cell 2016 Mar;29(3):270-284

Manchester Cancer Research Centre, Wellcome Trust Centre for Cell-Matrix Research, The University of Manchester, Michael Smith Building, Oxford Road, Manchester, M13 9PT, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.02.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796027PMC
March 2016

Novel Treatments in Development for Melanoma.

Cancer Treat Res 2016 ;167:371-416

University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-22539-5_16DOI Listing
January 2016

Working with Human Tissues for Translational Cancer Research.

J Vis Exp 2015 Nov 26(105). Epub 2015 Nov 26.

Department of Surgical Oncology, University of Texas MD Anderson Cancer Center;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3791/53189DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4692755PMC
November 2015

Raising the bar: optimizing combinations of targeted therapy and immunotherapy.

Ann Transl Med 2015 Oct;3(18):272

1 Department of Surgical Oncology; 2 Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2305-5839.2015.10.28DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630548PMC
October 2015

Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy.

Semin Oncol 2015 Aug 3;42(4):601-16. Epub 2015 Jun 3.

Department of Medical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00937754150010
Publisher Site
http://dx.doi.org/10.1053/j.seminoncol.2015.05.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955940PMC
August 2015

Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy.

Clin Cancer Res 2015 Jul 29;21(14):3102-4. Epub 2015 May 29.

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0363DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506225PMC
July 2015

Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma.

Cancer Res 2014 Dec 8;74(23):7037-47. Epub 2014 Oct 8.

Departments of Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas. Department of Systems Biology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-1392DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4347853PMC
December 2014

Universes collide: combining immunotherapy with targeted therapy for cancer.

Cancer Discov 2014 Dec 13;4(12):1377-86. Epub 2014 Nov 13.

Department of Medical Oncology, Massachusetts General Hospital and Harvard University, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-14-0477DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258160PMC
December 2014

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.

Cancer Biol Med 2014 Dec;11(4):237-46

1 Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA ; 2 Harvard Medical School, Boston, MA 02115, USA ; 3 Department of Melanoma Medical Oncology, 4 Department of Genomic Medicine, 5 Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7497/j.issn.2095-3941.2014.04.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296084PMC
December 2014

Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.

J Immunol 2014 Nov 24;193(9):4722-31. Epub 2014 Sep 24.

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030; University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030;

View Article

Download full-text PDF

Source
http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.1401160
Publisher Site
http://dx.doi.org/10.4049/jimmunol.1401160DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201984PMC
November 2014

RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma.

J Pigment Disord 2014 Nov 16;1(5). Epub 2014 Oct 16.

Division of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://omicsgroup.org/journals/raf-inhibitor-therapy-promote
Publisher Site
http://dx.doi.org/10.4172/2376-0427.1000139DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731654PMC
November 2014

The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα.

Cancer Discov 2014 Oct;4(10):1214-1229

Manchester Cancer Research Centre, Wellcome Trust Center for Cell Matrix Research, Faculty of Life Sciences, The University of Manchester, Michael Smith Building, Oxford Road, Manchester, M13 9PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-1007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184867PMC
October 2014

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma.

Oncoimmunology 2014 Oct 13;3(9):e954956. Epub 2014 Dec 13.

Division of Surgical Oncology; The University of Texas MD Anderson Cancer Center ; Houston, TX USA ; Genomic Medicine; The University of Texas MD Anderson Cancer Center ; Houston, TX USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/21624011.2014.954956DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292518PMC
October 2014

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.

Cancer Discov 2014 Jan 21;4(1):61-8. Epub 2013 Nov 21.

1Department of Medical Oncology, Dana-Farber Cancer Institute; 2Department of Medicine, Brigham and Women's Hospital; 3Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston; 4Broad Institute of Harvard and MIT; and 5Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0631DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947296PMC
January 2014

Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.

Cancer Discov 2013 Dec 8;3(12):1378-93. Epub 2013 Oct 8.

1Tumor Metastasis and Microenvironment Program and 2Molecular and Cellular Oncogenesis Program, The Wistar Institute; 3Abramson Cancer Center, University of Pennsylvania, Philadelphia; 4Lehigh Valley Health Network, Allentown, Pennsylvania; 5The National Institute on Aging, NIH, Baltimore, Maryland; and 6Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918498PMC
December 2013

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes.

Oncoimmunology 2013 Oct 15;2(10):e26615. Epub 2013 Oct 15.

Department of Surgical Oncology; University of Texas MD Anderson Cancer Center; Houston, TX USA ; Department of Genomic Medicine; University of Texas MD Anderson Cancer Center; Houston, TX USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.4161/onci.26615
Publisher Site
http://dx.doi.org/10.4161/onci.26615DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827093PMC
October 2013

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma.

Oncoimmunology 2013 May;2(5):e24320

Division of Surgical Oncology; Massachusetts General Hospital; Boston MA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.24320DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667913PMC
May 2013

Elucidating distinct roles for NF1 in melanomagenesis.

Cancer Discov 2013 Mar 21;3(3):338-49. Epub 2012 Nov 21.

Genetics Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-12-0313DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595355PMC
March 2013

Toll-like receptor agonists and febrile range hyperthermia synergize to induce heat shock protein 70 expression and extracellular release.

J Biol Chem 2013 Jan 4;288(4):2756-66. Epub 2012 Dec 4.

Division of Pulmonary and Critical Care, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M112.427336DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554941PMC
January 2013

Rapamycin induces the anti-apoptotic protein survivin in neuroblastoma.

Int J Biochem Mol Biol 2012 10;3(1):28-35. Epub 2012 Feb 10.

Department of Pediatrics, Division of Hematology-Oncology, The Warren Alpert Medical School of Brown University and Rhode Island Hospital 593 Eddy Street, Providence, RI, 02903, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325774PMC
October 2012

Histone deacetylase 6 (HDAC6) deacetylates survivin for its nuclear export in breast cancer.

J Biol Chem 2012 Mar 9;287(14):10885-93. Epub 2012 Feb 9.

Department of Pediatrics, The Warren Alpert Medical School of Brown University and Rhode Island Hospital, Providence, Rhode Island 02903, USA.

View Article

Download full-text PDF

Source
http://www.jbc.org/content/287/14/10885.full.pdf
Web Search
http://www.jbc.org/cgi/doi/10.1074/jbc.M111.308791
Publisher Site
http://dx.doi.org/10.1074/jbc.M111.308791DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322878PMC
March 2012

Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity.

J Biol Chem 2010 Nov 8;285(46):36129-37. Epub 2010 Sep 8.

Department of Pediatrics, Brown University and Rhode Island Hospital, Providence, Rhode Island 02903, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M110.152777DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2975235PMC
November 2010

Febrile range temperature represses TNF-alpha gene expression in LPS-stimulated macrophages by selectively blocking recruitment of Sp1 to the TNF-alpha promoter.

Cell Stress Chaperones 2010 Sep 10;15(5):665-73. Epub 2010 Mar 10.

Division of Pulmonary and Critical Care, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12192-010-0179-9
Publisher Site
http://dx.doi.org/10.1007/s12192-010-0179-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3006616PMC
September 2010

EGF regulates survivin stability through the Raf-1/ERK pathway in insulin-secreting pancreatic β-cells.

BMC Mol Biol 2010 Aug 31;11:66. Epub 2010 Aug 31.

Department of Pediatrics, Division of Pediatric Hematology-Oncology, Brown University, Providence, RI 02903, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2199-11-66DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940765PMC
August 2010

Facial resurfacing for nonmelanoma skin cancer prophylaxis.

Arch Dermatol 2006 Aug;142(8):976-82

Department of Dermatology, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/archderm.142.8.976DOI Listing
August 2006